Non-neoplastic bile duct disorder
MONDO:0006322A non-neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts. Representative examples include cholangitis and biliary atresia.
Also known as: non-neoplastic bile duct disorder
175 clinical trials for this condition and its sub-types, 0 tagged with Non-neoplastic bile duct disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Non-neoplastic bile duct disorder
-
Cholangitis 17 trials · 139 incl. sub-types
9 sub-types
- Cholecystitis 35 trials · 65 incl. sub-types Sub-types →
- Sclerosing cholangitis 3 trials · 57 incl. sub-types Sub-types →
- Acute cholangitis 7 trials · 42 incl. sub-types Sub-types →
- Autoimmune cholangitis 1 trial
- Ascending cholangitis 0 trials
- Chronic cholangitis 0 trials
- Pericholangitis 0 trials
- Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome 0 trials
- Suppurative cholangitis 0 trials
-
Biliary atresia 24 trials
3 sub-types
-
Obstructive jaundice 11 trials
-
Caroli disease 1 trial
-
Extrahepatic cholestasis 0 trials
1 sub-type
- Mirizzi syndrome 0 trials
Most studied deeper sub-types
-
Liver drug trial for kids with biliary atresia ends early
Disease control Stopped earlyThis study tested the drug obeticholic acid in children with biliary atresia who had already undergone Kasai surgery. The goal was to see if the drug could improve outcomes like avoiding liver transplant or death. The trial was terminated early and enrolled only 28 participants, …
Phase 2/3 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug A3907 tested for rare liver disease, study halted early
Disease control Stopped earlyThis study tested a drug called A3907 in 18 adults with Primary Sclerosing Cholangitis (PSC), a rare liver disease. The goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.
Phase 2 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Antibiotic vancomycin tested as PSC treatment – trial stopped early
Disease control Stopped earlyThis study tested whether the antibiotic vancomycin, taken by mouth, is safe and effective for adults with primary sclerosing cholangitis (PSC), a rare liver disease. About 102 participants were randomly assigned to receive vancomycin or a placebo. The main goal was to see if van…
Phase 2/3 • Sponsor: Elizabeth Carey • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Blood test may tame the tightrope walk of transplant drugs
Diagnosis Stopped earlyThis study tests whether a blood test called TruGraf can help doctors fine-tune immunosuppression medications in liver transplant recipients with autoimmune liver diseases like autoimmune hepatitis, primary sclerosing cholangitis, or primary biliary cirrhosis. The test measures g…
Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC